Hims & Hers Health, Inc.
About Hims & Hers Health, Inc.
Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $2.3B
- Net income
- $128.4M
- Total assets
- $2.2B
- Market cap
- $6.1B
- Gross margin
- 73.8%
- Operating margin
- 4.5%
- Net margin
- 5.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.3B
- Cost of revenue
- $614.3M
- Gross profit
- $1.7B
- Operating expenses
- $1.6B
- Operating income
- $105.6M
- Income tax
- -$4.4M
- Net income
- $128.4M
- EPS (basic)
- $0.57
- EPS (diluted)
- $0.51
Balance sheet
- Total assets
- $2.2B
- Current assets
- $767.6M
- Total liabilities
- $1.6B
- Current liabilities
- $404.4M
- Shareholders’ equity
- $540.9M
Cash flow
- Operating cash flow
- $300.0M
- Investing cash flow
- -$1.0B
- Financing cash flow
- $729.6M
- Net cash flow
- $7.2M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $6.1B
- P/E ratio
- 53.3
- EPS (diluted)
- $0.51
- Shares outstanding
- 223.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 21, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $128.4M in FY2025.
- Revenue grew 763% from FY2021 to FY2025.
- Gross margin of 73.8%, net margin 5.5%.
- Trading 59% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 53.3.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Hims & Hers Health, Inc..
Write a review
News about Hims & Hers Health, Inc.
News & sentiment via Polygon.io
